US DoD NMRC Reports Positive Response to Vaccine
Filed with ASX · · 3 pages · English
Key Points • NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETEC • Immuron executes a Research Agreement with PCI Clinical Services to manufacture drug product • Two human phase II clinical trials to be conductedin 2021 by the US NMRC • One trial will focus ETEC infections • The second trial will focus on the ability of the hyperimmune product to protec
Story so far
Earlier from Immuron
- Immuron Travelers Diarrhea Market Update
- Appendix 4E and 2020 Financial Report
- Immuron Announces US$20.0 Million Registered Direct Offering
- Immuron Reports Neutralizing activity Against SARS-CoV-2
- US DoD Receives FDA Guidance on clinical development plans
Later from Immuron
- Immuron Receives AUD $358,280 R&D Tax Concession Refund
- Immuron SARS-CoV-2 Research Agreement with Monash University
- IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
- Pause in Trading
- Voluntary Suspension
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron